All patients N = 5276 | Europe N = 2622 | USA N = 1933 | China N = 721 | |
---|---|---|---|---|
Agea, years | ||||
Mean (SD) | 60.9 (14.3) | 62.5 (15.1) | 59.8 (14.2) | 58.3 (10.1) |
Median | 62 | 65 | 61 | 59 |
Min, Max | 18, 89 | 18, 89 | 18, 89 | 22, 89 |
> 90 years old, n (%) | 42 (0.8%) | 25 (1.0%) | 17 (0.9%) | 0 (0.0%) |
Sex, n (%) | ||||
Female | 2259 (43%) | 1067 (41%) | 869 (45%) | 323 (45%) |
Male | 3017 (57%) | 1555 (59%) | 1064 (55%) | 398 (55%) |
BMI, kg/m2 | ||||
Mean (SD) | 26.9 (5.8) | 26.5 (4.9) | 29.2 (6.4) | 22.4 (3.2) |
Median | 25.9 | 25.8 | 28.1 | 22.0 |
Min, Max | 13, 74 | 15, 74 | 13, 70 | 14, 47 |
Unknown, n (%) | 162 (3.1%) | 94 (3.6%) | 61 (3.2%) | 7 (1.0%) |
Ethnic origin, n (%) | ||||
White/Caucasian | 2991 (57%) | 1928 (74%) | 1063 (55%) | 0 (0%) |
Chinese | 754 (14%) | 2 (0%) | 37 (2%) | 715 (100%) |
African American | 517 (10%) | 5 (0%) | 512 (27%) | 0 (0%) |
Hispanic/Latino | 248 (5%) | 51 (2%) | 197 (10%) | 0 (0%) |
North/Western/Middle EU | 437 (8%) | 437 (17%) | 0 (0%) | 0 (0%) |
Asian - other | 76 (1%) | 12 (0%) | 64 (3%) | 0 (0%) |
Otherb | 241 (5%) | 181 (7%) | 59 (3%) | 1 (0%) |
Unknown | 12 (< 1%) | 6 (< 1%) | 1 (< 1%) | 5 (< 1%) |
Employment status, n (%) | ||||
Employedc | 1265 (24%) | 593 (23%) | 574 (30%) | 98 (14%) |
Retired | 2555 (49%) | 1356 (52%) | 719 (37%) | 480 (67%) |
Otherd | 1287 (24%) | 607 (23%) | 558 (29%) | 122 (17%) |
Unknown | 169 (3%) | 66 (3%) | 82 (4%) | 21 (3%) |
Current Hb level, g/dL | ||||
Mean (SD) | 11.5 (1.9) | 11.6 (1.8) | 11.8 (1.9) | 10.8 (1.7) |
Median | 11.5 | 11.6 | 11.5 | 11.0 |
Min, Max | 3, 21 | 3, 19 | 6, 21 | 4, 19 |
Unknown, n (%) | 485 (9.2%) | 214 (8.2%) | 247 (12.8%) | 24 (3.3%) |
Current Hb level, n (%) | ||||
Hb < 8 g/dL | 141 (3%) | 95 (4%) | 17 (1%) | 29 (4%) |
Hb 8–10 g/dL | 533 (10%) | 206 (8%) | 197 (10%) | 130 (18%) |
Hb 10–12 g/dL | 2464 (47%) | 1216 (46%) | 834 (43%) | 414 (57%) |
Hb > 12 g/dL | 1653 (31%) | 891 (34%) | 638 (33%) | 124 (17%) |
Unknown | 485 (9%) | 214 (8%) | 247 (13%) | 24 (3%) |
Current CKD stage, n (%) | ||||
Stage 3a NDD | 821 (16%) | 397 (15%) | 274 (14%) | 150 (21%) |
Stage 3b NDD | 983 (19%) | 523 (20%) | 310 (16%) | 150 (21%) |
Stage 4 NDD | 1492 (28%) | 753 (29%) | 462 (24%) | 277 (38%) |
Stage 5 NDD | 57 (1%) | 31 (1%) | 24 (1%) | 2 (0%) |
DD | 1923 (36%) | 918 (35%) | 863 (45%) | 142 (20%) |
Underlying cause of CKDe, n (%) | ||||
Hypertension | 3070 (59%) | 1417 (54%) | 1285 (67%) | 368 (51%) |
Type 2 Diabetes | 2034 (39%) | 928 (36%) | 812 (42%) | 294 (41%) |
Cardiovascular disease | 888 (17%) | 454 (17%) | 359 (19%) | 75 (10%) |
Glomerulonephritis | 883 (17%) | 391 (15%) | 156 (8%) | 336 (47%) |
Unknown | 34 (1%) | 14 (1%) | 17 (1%) | 3 (0%) |
Comorbid conditionsf, n (%) | ||||
Hypertension | 2350 (78%) | 1044 (82%) | 857 (84%) | 449 (62%) |
Type 2 diabetes | 1199 (40%) | 430 (34%) | 497 (49%) | 272 (38%) |
Dyslipidemia | 877 (29%) | 335 (26%) | 449 (44%) | 93 (13%) |
Coronary heart disease | 536 (18%) | 206 (16%) | 196 (19%) | 134 (19%) |
Depression | 366 (12%) | 151 (12%) | 175 (17%) | 40 (6%) |
Anxiety | 321 (11%) | 152 (12%) | 144 (14%) | 25 (3%) |
Atherosclerosis | 319 (11%) | 162 (13%) | 100 (10%) | 57 (8%) |
No comorbidities | 400 (13%) | 131 (10%) | 35 (3%) | 234 (32%) |
Unknown | 2260 (43%) | 1350 (51%) | 910 (47%) | 0 (0%) |
Type of anemia treatment currently receivedg, n (%) | N = 1209 | N = 548 | N = 384 | N = 277 |
Oral iron only | 315 (26%) | 77 (14%) | 139 (36%) | 99 (36%) |
IV iron only | 79 (7%) | 54 (10%) | 14 (4%) | 11 (4%) |
ESA only | 258 (21%) | 126 (23%) | 101 (26%) | 31 (11%) |
Both oral iron and ESA | 227 (19%) | 107 (19%) | 33 (9%) | 87 (31%) |
Both IV iron and ESA | 330 (27%) | 184 (34%) | 97 (25%) | 49 (18%) |